Cabaletta Bio
CABA
108 hedge funds and large institutions have $87.2M invested in Cabaletta Bio in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 37 closing their positions.
184% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $371K
60% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 25
10% less funds holding
Funds holding: 120 → 108 (-12)
19.73% less ownership
Funds ownership: 98.36% → 78.63% (-20%)
32% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 37
62% less capital invested
Capital invested by funds: $227M → $87.2M (-$140M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Superstring Capital Management
New York
|
+$2.42M |
| 2 |
Morgan Stanley
New York
|
+$2.14M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.1M |
| 5 |
Two Sigma Advisers
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$11M |
| 2 |
VA
VR Adviser
New York
|
-$7.38M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.24M |
| 4 |
FAM
Fred Alger Management
New York
|
-$6.33M |
| 5 |
SC
Stempoint Capital
New York
|
-$6.03M |
CABA Hedge Fund Activity: Q4 2024 in Review
108 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q4 2024, worth a combined $87.2M — down 62% from $227M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CABA and 25 opened new positions — a net loss of 12 holders — while 25 trimmed existing stakes and 40 added.
The largest buyer was Superstring Capital Management, adding an estimated $2.42M. The largest seller was Jennison Associates, cutting an estimated $11M.
- 108 institutional investors held Cabaletta Bio (CABA) as of Q4 2024, down from 120 in Q3 2024.
- Funds reported $87.2M of Cabaletta Bio stock for Q4 2024, down 62% quarter-over-quarter.
- 25 funds opened new Cabaletta Bio positions in Q4 2024 and 37 closed out, a net change of -12 holders.
- The largest Cabaletta Bio buyer in Q4 2024 was Superstring Capital Management, an estimated $2.42M added.
- The largest Cabaletta Bio seller in Q4 2024 was Jennison Associates, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2024.